Global X Guru™ Activist ETF

Most Recent

  • uploads///Xifaxan
    Company & Industry Overviews

    A Post-3Q17 Update on Key Valeant Branded Drugs: Xifaxan, Apriso, and Glumetza

    In 3Q17, Valeant’s Xifaxan reported revenues of $286 million, which was ~5% higher on a YoY (year-over-year) basis and a 23% rise quarter-over-quarter.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    VRX’s Gastrointestinal Segment Saw Robust Revenue Growth in 2016

    In 3Q16, Valeant Pharmaceuticals’s (VRX) Gastrointestinal product segment witnessed a drop in revenues due to unfavorable changes in drug pricing.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.